As we previously reported, on July 10, 2019, Genentech filed motions for a temporary restraining order and preliminary injunction against Amgen in the Genentech v. Amgen BPCIA litigation related to Amgen’s trastuzumab biosimilar KANJINTI (trastuzumab-anns). Yesterday, the District Court denied Genentech’s motions and lifted the standstill order given during the July 10, 2019 teleconference. The Court’s opinion is currently under seal, but the Court stated that it will unseal its opinion today at 4:00 p.m. unless the parties provide proposed redactions by 2:30 p.m.
Yesterday, Amgen announced that “MVASI (bevacizumab-awwb), a biosimilar to Avastin® (bevacizumab), and KANJINTI (trastuzumab-anns), a biosimilar to Herceptin® (trastuzumab), are now available in the United States.”
The post Court Denies TRO/PI in Genentech v. Amgen; Amgen Announces Launch appeared first on Big Molecule Watch.